Steven Daniel Schwartz, Director at Avalanche Biotechnologies, Inc. ([AAVL]), sold 17,250 shares at $36.81 ($625K) on 2015-06-01, disclosed to the SEC on 2015-06-02.
Scheduled sale ($625k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $36.11 | 14,157 | $511K | 81.8% |
| 2 | $36.81 | 3,093 | $114K | 18.2% |
| Total | $36.24 avg | 17,250 | $625K | 100% |
| Filing → |
| AAVL | SELL | 2015-05-11 | $570K | — | Filing → |
| AAVL | SELL | 2015-04-23 | $652K | — | Filing → |
| AAVL | SELL | 2015-04-13 | $685K | — | Filing → |